Search

Displaying results 1471 - 1480 of 10000 in total
  1. Drug

    Votucalis

    go.drugbank.com/drugs/DB05032
    Investigational

    rEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.

  2. Drug

    Peginterferon beta-1a

    go.drugbank.com/drugs/DB09122
    ApprovedInvestigational

    [A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. … [L5801] MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.

    Categories: Compounds used in a research, industrial, or household settingProducts: PLEGRIDY®94 UG SOLUCIÓN INYECTABLE., BLASTOFERON® 44 µG SOLUCIÓN INYECTABLE
  3. Drug

    Iothalamic acid

    go.drugbank.com/drugs/DB09133
    Approved

    Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent.

    Categories: Diagnostic Uses of Chemicals, Compounds used in a research, industrial, or household setting
  4. Drug

    Sodium phosphate, monobasic, unspecified form

    go.drugbank.com/drugs/DB14503
    Approved

    Mixtures: 500mL of Blood, Reveos Select CPD with AS-5 Red Cell Preservative Solution For Collection Of 500ml Of Blood
  5. Drug

    Etretinate

    go.drugbank.com/drugs/DB00926
    ApprovedWithdrawn

    The mechanism of action of etretinate is still incompletely understood although, like retinoic acid, it is thought to interfere with the terminal differentiation of keratinocytes. … Etretinate is also believed to enhance the binding of cAMP to the regulatory RI subunit of cAMP dependent protein kinases.

    Categories: Retinoids for Treatment of Psoriasis
  6. Drug

    CYP-001

    go.drugbank.com/drugs/DB15739
    Investigational

    These cells have advantage over other MSCs because a large amount can be obtained from a single healthy blood donor, negating the risks from donor-and expansion dependent variability.

  7. Drug

    Iotroxic acid

    go.drugbank.com/drugs/DB08945
    ApprovedWithdrawn

    Iotroxic acid is a contrast medium molecule.

    Categories: Diagnostic Uses of Chemicals, Compounds used in a research, industrial, or household setting
  8. Drug

    Indium In-111 chloride

    go.drugbank.com/drugs/DB09490
    Approved

    It is supplied as a sterile, pyrogen-free solution of Indium ("'In) Chloride in O.04M HCI. … Indium In-111 Chloride is a diagnostic radiopharmaceutical agent intended for radiolabeling OncoScint (satumomab pendetide) or ProstaScint (capromab pendetide) used for _in vivo_ diagnostic imaging procedures

    Mixtures: Kit for the Preparation of Indium In 111 Pentetreotide
  9. Drug

    Everolimus

    go.drugbank.com/drugs/DB01590
    ApprovedInvestigational

    Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. … In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

    Categories: Mammalian target of rapamycin (mTOR) kinase inhibitorsSynonyms: 40-O-(2-hydroxyethyl)-rapamycin, 42-O-(2-Hydroxyethyl)rapamycin
  10. Drug

    Camizestrant

    go.drugbank.com/drugs/DB19218
    ApprovedInvestigational

    [L64094,L64107] The European Commission approved camizestrant on July 23, 2026, Health Canada authorized it on August 4, 2026, and the FDA granted accelerated approval on September 4, 2026. … [L64094,L64107] In pre- or peri-menopausal women and in men, camizestrant plus a CDK4/6 inhibitor is combined with an LHRH agonist or antagonist.